A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder

Progress in Neuropsychopharmacology and Biological Psychiatry

Volumn 18, Issue 3, 1994, Pages 447-463

  Cutler, Neal R ^a   Keppel Hesselink, Jan M ^b   Sramek, John J ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b NONE

Author keywords

5 hydroxytryptamine; anxiolytic; serotonin

Indexed keywords

BENZODIAZEPINE DERIVATIVE; IPSAPIRONE; PLACEBO; SEROTONIN RECEPTOR;

ADULT; ANXIETY NEUROSIS; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; SEDATION; SIDE EFFECT; VERTIGO;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DIAZEPAM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES;

EID: 0028302190     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/0278-5846(94)90003-5     Document Type: Article

References (44)

1. Gepirone hydrochloride
2. Efficacy and safety of a putative anxiolytic agent: ipsapirone
3. Managing long-term therapy for panic disorder
4. 1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat
5. Different effects of intracerebral and systemic administration of buspirone in the forced swimming test: involvement of a metabolite
6. 1A receptor ligands 8-OH-DPAT and ipsapirone in the rat
7. 1A receptors in anxiety
8. 25 years of benzodiazepine experience: clinical commentary on use, abuse, and withdrawal
9. 1 binding sites as target for a novel putative anxiolytic
10. 1A receptors and anxiety
11. Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze
12. Serotonin-1A anxiolytics: An overview
13. Brain serotonin and blood pressure regulation: studies using in vivo electrochemistry and direct tissue assay
14. Buspirone metabolite and panic attacks
15. Metabolism and disposition of buspirone
16. Lack of interaction between cimetidine and buspirone
17. Autoradiographic identification and topographical analyses of high affinity serotonin receptor subtypes as a target for the novel putative anxiolytic TVX Q 7821
18. Comparative effects on body weight, food intake and temperature of withdrawal from ipsapirone and chlordiazepoxide in rats
19. Alpha 2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonflict test in the rat
20. Benzodiazepines (First of Two Parts)
21. The assessment of anxiety states by rating
22. A RATING SCALE FOR DEPRESSION
23. Ipsapirone: Evidence for efficacy in depression
24. Single administration of 5-HT1A agonists decreases 5-HT1 A presynaptic, but not postsynaptic receptor-mediated responses: relationship to antidepressant-like action
25. Promising anxiolytics? A new class of drugs: the azapirones
26. Differentiating anxiety and depression in anxiety disorders: Use of rating scales
27. 1-(2-Pyrimidinyl)-piperazine may alter the effects of 5-HT1A agonists in the learned helplessness paradigm in rats
28. Prevalence and correlates of long-term regular use of anxiolytics
29. Mechanism of action of anxiolytic drugs
30. Evidence that the putative 5-HT1A receptor agonists 8-OH-DPAT and ipsapirone have a central hypotensive action that differs from that of clonidine in anaesthetized cats.
31. Replication of factors of psychopathology in interview, ward behavior, and self-report ratings of hospitalized depressives
32. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression
33. Anxiety
34. Neurophysiological effects of buspirone and ipsapirone in the hippocampus: comparison with 5-hydroxytryptamine
35. Pharmacokinetics of the azapirones
36. Simultaneous quantitation of buspirone and 1-(2-pyrimidinyl) piperazine in human plasma and urine by capillary gas chromatography-mass spectrometry
37. Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery's conflict test
38. High potency benzodiazepines for short-term management of panic disorder: the U.S. experience
39. Dependence as a limiting factor in the clinical use of minor tranquilizers
40. Evidence for the localization of 5HT1 A binding sites on serotonin containing neurons in the raphe dorsalis and raphe centralis nuclei of the rat brain
41. The differentiation of anxiety and depressive disorders: a biometric approach